Thanks to science, vaccines have helped us fight many potentially fatal or debilitating diseases. This #NationalImmunizationAwarenessMonth, we encourage everyone to learn more about the vaccines available to them, and to consider joining a clinical trial to support the next generation of live-saving vaccines. Learn more at buff.ly/3qtsXed. #NIAM #PowerToProtect #vaccines #clinicalresearch
Velocity Clinical Research, Inc.
Biotechnology Research
Durham, North Carolina 22,118 followers
Delivering high-quality clinical trial data and patient care with unprecedented efficiency.
About us
Velocity is the world’s leading organization of fully integrated clinical research sites. With 90 sites and more than 220 investigators, Velocity partners with pharmaceutical and biotechnology companies to research new drugs, medical devices, diagnostics, and combination products that could improve human health and wellbeing. Velocity offers unified research site solutions to efficiently provide the right patients, investigators, and research staff for clinical trials across the U.S. and Europe. The company also operates a technology hub in India, where it is unlocking a new era in clinical research by developing innovative systems to leverage expansive site, patient, and historical performance data. To learn more about how Velocity delivers high-quality data, exemplary patient care, and unprecedented efficiency for clinical trials at any scale, visit VelocityClinical.com.
- Website
-
https://velocityclinical.com
External link for Velocity Clinical Research, Inc.
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- Durham, North Carolina
- Type
- Privately Held
- Founded
- 2018
- Specialties
- Clinical trials, Patient Recruitment, Vaccine Research, Pharmaceutical Research, Clinical Research, Vaccines, Neurology, Pediatrics, NASH, Infectious Disease, Dermatology, Women's Health, Gastroenterology, Alllergy, Medical Devices, Research Sites, Principal Investigators, and Drug Development
Locations
Employees at Velocity Clinical Research, Inc.
Updates
-
Jennifer Carl introduces this edition of The Recap, spotlighting our Growth & Development team's impact and exploring how Velocity continues to scale up while maintaining the agility needed to support trials of all sizes. Topics include: • A milestone in improving patient stipend payments • Continued expansion in the U.S. and across Europe Subscribe to The Recap here on LinkedIn or at https://lnkd.in/grZdGsK4
-
Last week, at the request of the U.S. Department of State and the Cleveland Council on World Affairs, our Cleveland site hosted scientists and researchers from Kazakhstan to share our perspectives and experiences in conducting clinical trials. Principal Investigators Gerald Cephas, M.D., and Margaret Rhee, MD, gave our guests a tour of the facility and answered questions. Thank you, Drs. Cephas and Rhee, for sharing your decades of research experience!
-
This is why we do what we do. Velocity sites and investigators have supported research for nine products that have received U.S. FDA approval in 2024. These include: • Madrigal Pharmaceuticals' Rezdiffra (resmetirom), the first FDA-approved #MASH drug. • Moderna's mRESVIA, an mRNA RSV vaccine for adults 60 and older. • Eli Lilly and Company's Kisunla (donanemab) for patients with early symptomatic Alzheimer's. • Ipsen's Iquirvo, the first primary biliary cholangitis treatment approved by the FDA in over a decade, with significant contributions from our own Kris Kowdley, MD, the primary investigator for the Phase 3 trial. • Pfizer’s Penbraya, a meningococcal vaccine for people aged 10 to 25. To date, Velocity sites and investigators have contributed to research for over 60 product approvals, including more than 20 since 2023. Once again, we're grateful to our patients, employees, clients, and partners who make this progress possible. The journey continues… #ClinicalTrials #ClinicalResearch #CARECouncils
-
With more than 200 investigators, Brandon Essink, MD, CPI, and his team are finding new ways to both support new investigators and leverage world-class PI expertise to increase knowledge sharing with Sponsors and CROs. Internally, Velocity's Principal Investigator Onboarding and Training (PIVOT) program gives new and veteran PIs unparalleled educational opportunities. For clients, Velocity PIs are increasingly playing a role in early protocol review. Each Velocity CARE Council is led by experienced physicians — their research experience and real-world clinical expertise are valuable for assessing inclusion/exclusion criteria and potential patient reach, and improving study design viability. More about CARE Councils: https://lnkd.in/gXRstKuH More about the PIVOT program: https://lnkd.in/gS6h2QJy #ClinicalTrials #PrincipalInvestigators #CARECouncils
-
Our sites in Leipzig, Germany and High Wycombe, UK, have recently relocated to larger, more accessible facilities. The moves enable us to accommodate a higher volume of patient visits and provide enhanced capabilities in purpose-built sites. Swipe through the slides below to get a glimpse of our new locations.
-
When people like you join a clinical trial, scientists may be able to uncover better ways to treat conditions that may affect you, your loved ones, and future generations. Velocity is now enrolling people of all ages for new and upcoming studies. Beyond helping advance medicine, you may also: • Learn about potential new medicines in development • Get study-related medical exams at no cost • Receive compensation for participating (available amounts may differ for each study) Each participant could bring us one step closer to a healthier future. Ready to make a difference? Sign up for more info at https://buff.ly/3Y9oFHg #ClinicalTrials #MedicalResearch
-
We’re thrilled to welcome Mike Zaranek as Chief Financial Officer. Mike brings nearly three decades of experience in the life-sciences industry in senior financial and corporate development leadership roles, having previously held roles at IQVIA and Science 37. He will direct the company’s financial goals and accounting, and advise on the Velocity's strategic direction. Paul Evans, President and CEO of Velocity remarked on the appointment, “Velocity has grown exponentially in the past three years since the GHO acquisition. That brings with it a different set of challenges to manage whilst ensuring we deliver on strategic goals. Attracting top talent from major organizations, like Mike, demonstrates the ambitious goals we have as an organization to scale, and scale for a purpose. Mike and his team are a strategic part of that and I look forward to working with him to deliver Velocity’s next stage of growth.” Read the coverage of this appointment on Yahoo Finance: https://lnkd.in/g4pRv8nF Join us in welcoming Mike!
-
Attending Pri-Med West later this week in #Anaheim? Visit booth 432 to connect with Mary Hughes, Modesto Carrillo, Dafne Yagupsky, M.D., Maria Morales, John Nelson, Patricia Gonzalez, and Jennifer Huynh! Meet our team to learn more about clinical trials at Velocity, opportunities at our SoCal sites, and our capabilities across 90+ sites worldwide. #PriMedWest
-
Velocity has now paid more than $1.1 million in patient study stipends through our VISION Engage app. Here's why this matters: Patients get: • Prompt, secure in-app payments • Direct bank transfers or virtual debit card options • Enhanced visibility and flexibility Sites get: • Seamless integration with existing workflows • Reduced administrative burden • Improved patient satisfaction and retention Explore more about VISION, Velocity’s AI-enabled data and technology platform: https://lnkd.in/gpZECMhS Congratulations to Raghu Punnamraju, Sweta Pittala, Sneha Raj, PMP, and our entire team in Hyderabad for reaching this milestone! #VISION #AI #PatientRecruitment #ClinicalTrials